Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Vascular Solutions

Health Tech & Medtech · Maple Grove, United States · Founded 1997 · IPO 2008 Unicorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$1.00B
Market cap · 2026

Investors

2 investors on Vascular Solutions's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series B+ 2 investors entered at this stage

Patent intelligence

$33M patent portfolio · 27 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value
$33M
3.3% of market cap · 7.4× smaller than top peer HeartFlow ($247M)
27 active patent families
Where Vascular Solutions innovates Blood vesselBiomedical engineeringGeneral surgeryCatheter deviceGuide wires
Above peer median on Legal

Quality vs same-sector peers

Vascular Solutions on the five Patsnap quality dimensions

Vascular Solutions in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where Vascular Solutions concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Vascular Solutions and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Vascular Solutions on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.